• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经颈静脉肝内门体分流术治疗转移性肝癌所致门静脉高压性顽固性腹水

Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease.

作者信息

Geeroms Barbara, De Hertogh Gert, Vanslembrouck Ragna, Wildiers Hans, Nevens Frederik, Maleux Geert

机构信息

Department of Radiology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

Department of Pathology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

出版信息

J Vasc Interv Radiol. 2018 Dec;29(12):1713-1716. doi: 10.1016/j.jvir.2018.08.007. Epub 2018 Nov 2.

DOI:10.1016/j.jvir.2018.08.007
PMID:30392802
Abstract

Three patients with a medical history of breast carcinoma and metastatic carcinomatous liver disease associated with severe portal hypertension and refractory ascites are presented. Transjugular intrahepatic portosystemic shunt creation was considered as a palliative treatment option and a valuable alternative to regular paracenteses in these patients. In 2 of the 3 patients, the refractory ascites was controlled for several months without need for paracentesis, and subsequently transjugular intrahepatic portosystemic shunt may provide valuable palliation and ascites control in patients with refractory ascites due to breast cancer-induced pseudocirrhosis.

摘要

本文介绍了3例有乳腺癌病史且伴有严重门静脉高压和难治性腹水的转移性癌性肝病患者。经颈静脉肝内门体分流术被视为一种姑息性治疗选择,是这些患者常规腹腔穿刺术的一种有价值的替代方法。在这3例患者中的2例中,难治性腹水得到了数月的控制,无需进行腹腔穿刺术,随后经颈静脉肝内门体分流术可能为因乳腺癌所致假性肝硬化引起的难治性腹水患者提供有价值的姑息治疗和腹水控制。

相似文献

1
Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease.经颈静脉肝内门体分流术治疗转移性肝癌所致门静脉高压性顽固性腹水
J Vasc Interv Radiol. 2018 Dec;29(12):1713-1716. doi: 10.1016/j.jvir.2018.08.007. Epub 2018 Nov 2.
2
The Role of TIPS in patients with Refractory Ascites and Portal Vein Thrombosis.经颈静脉肝内门体分流术在难治性腹水和门静脉血栓形成患者中的作用
Ann Hepatol. 2017 Jul-Aug;16(4):619-620. doi: 10.5604/01.3001.0010.0310.
3
Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.肝硬化患者经颈静脉肝内门体分流术置入后的发病率和死亡率。
Eur J Gastroenterol Hepatol. 2019 May;31(5):626-632. doi: 10.1097/MEG.0000000000001342.
4
Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.经颈静脉肝内门体分流术在腹水和肝肾综合征治疗中的应用
Eur J Gastroenterol Hepatol. 2006 Nov;18(11):1143-50. doi: 10.1097/01.meg.0000236872.85903.3f.
5
Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.经颈静脉肝内门体分流术治疗顽固性腹水前后的尿水通道蛋白-2排泄情况
Scand J Gastroenterol. 2015 Apr;50(4):454-61. doi: 10.3109/00365521.2014.962610. Epub 2015 Jan 30.
6
Tips for TIPS: A combined percutaneous and transjugular approach for intrahepatic portosystemic shunt placement after liver transplant.Tips for TIPS:肝移植后经皮经肝联合途径建立肝内门体分流术。
Ann Hepatol. 2021 May-Jun;22:100162. doi: 10.1016/j.aohep.2019.11.005. Epub 2019 Dec 3.
7
The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.经颈静脉肝内门体分流术(TIPS)在门静脉高压症治疗中的作用。
J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S344-51. doi: 10.1097/MCG.0b013e318157e500.
8
Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.经颈静脉肝内门体分流术治疗肝移植受者难治性腹水:临床转归。
J Vasc Interv Radiol. 2010 Feb;21(2):218-23. doi: 10.1016/j.jvir.2009.10.025.
9
Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.经颈静脉肝内门体分流术联合其他干预措施治疗门静脉高压性肝细胞癌
World J Gastroenterol. 2015 Nov 21;21(43):12439-47. doi: 10.3748/wjg.v21.i43.12439.
10
Correlation between portal/hepatic vein gradient and response to transjugular intrahepatic portosystemic shunt creation in refractory ascites.门静脉/肝静脉梯度与经颈静脉肝内门体分流术治疗顽固性腹水疗效的相关性
J Vasc Interv Radiol. 2004 Dec;15(12):1431-4. doi: 10.1097/01.RVI.0000141341.98441.0E.

引用本文的文献

1
Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature.假性肝硬化:一组病例系列,伴有临床和影像学相关性,并复习文献。
Dig Dis Sci. 2024 Mar;69(3):1004-1014. doi: 10.1007/s10620-023-08226-3. Epub 2024 Jan 4.
2
Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.经颈静脉肝内门体分流术(TIPS)在 HCC 及其他肝脏恶性肿瘤中的风险和获益:文献综述。
BMC Gastroenterol. 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0.
3
Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis.
转移性癌症患者的假性肝硬化和门静脉高压:系统评价和荟萃分析。
Sci Rep. 2022 Nov 18;12(1):19865. doi: 10.1038/s41598-022-24241-2.
4
Pseudocirrhosis Due to Desmoplastic Response to Chemotherapy in Breast Cancer Liver Metastases.乳腺癌肝转移化疗后促结缔组织增生反应所致假肝硬化
Cureus. 2022 May 25;14(5):e25321. doi: 10.7759/cureus.25321. eCollection 2022 May.
5
Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis.经颈静脉肝内门体分流术治疗症状性恶性假性肝硬化
J Gastrointest Oncol. 2022 Feb;13(1):279-287. doi: 10.21037/jgo-21-501.
6
Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity.转移性乳腺癌合并假性肝硬化:一种未知的临床实体。
ESMO Open. 2020 Jun;5(3):e000695. doi: 10.1136/esmoopen-2020-000695.